Proteomics
tumor, SD
CPS, TUMOR
Tissue PD-L1 expression pre- and post-olaparib–based treatment was assessed by combined positive score (CPS). PD-L1 CPS was higher in 74.2% posttreatment samples in all three olaparib-treated arms, but not in the control arm. CPS was higher in 8 out of 12 tissue samples (Baseline (up) and after treatment (down) images in Patient A (Cisplatin-Olaparib arm) and B (Olaparib arm), respectively, showing dramatic tumor volumetric decrease. Both patients had SD on imaging based on RECIST. Representative immunofluorescence (IF) images at baseline (up) and after treatment (down), highlighting changes in Ki67 (red), PD-L1 (white), STING (magenta) in tumor. Nuclei (blue) and cytokeratin (green) are also shown. A posttreatment decrease in Ki-67 (measured by QIF) was noticed in both patients.